ALEC - NASDAQ
Alector, Inc.
$1.86
-1.3%Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotAlector, Inc. Management Team
Mr. Neil Berkley M.B.A., M.S.
Chief Business Officer
Dr. Marc Grasso M.D.
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Compensation
$703,249
Mr. Giacomo Salvadore M.D.
Chief Medical Officer
Ms. Clare Hunt M.B.A.
Chief People Officer
Ms. Kristina Cutter M.P.H.
Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer
Ms. Virginia DeJesus-Rueff M.B.A.
Chief of Staff & Head of Strategy
Dr. Arnon Rosenthal Ph.D.
Co-Founder, Chief Executive Officer & Director
Compensation
$888,566
Ms. Danielle Pasqualone J.D., Ph.D.
General Counsel
Dr. Saraswati Kenkare-Mitra Ph.D.
President and Head of Research & Development
Compensation
$1,184,681
Ms. Katie Hogan
Senior Director of Corporate Communication & Investor Relations
Alector, Inc. Insider Positioning
During the last 12 months, insiders have purchased $224K and sold $793K worth of ALEC shares, resulting in $568K of net selling activity.
3 Months
0
0.00
2.8K
7.47K
-7K
-$7K
3-6 Months
0
0.00
127.0K
271.12K
-271K
-$271K
6-9 Months
0
0.00
196.1K
219.98K
-220K
-$220K
9-12 Months
148.1K
224.19K
127.8K
293.99K
-70K
-$70K
Top Buyers
Rosenthal Arnon
Director, Officer: Chief Executive Officer
$65K
Kenkare-Mitra Sara
Officer: President And Head Of R&D
$26K
Berkley Neil Lindsay
Officer: Principal Financial Officer
$26K
Yaffe Kristine
Director
$15K
Garofalo Elizabeth A.
Director
$15K
Top Sellers
Rosenthal Arnon
Director, Officer: Chief Executive Officer
$419K
Berkley Neil Lindsay
Officer: Cfo & Chief Business Officer
$159K
Kenkare-Mitra Sara
Officer: President And Head Of R&D
$106K
Wong-Sarad Grace
Officer: Principal Accounting Officer
$74K
Hammond Paula
Director
$33K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $568K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
ALEC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 21, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 24, 2025 | April 22, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | June 12, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 27, 2023 | April 27, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 16, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2021 | June 17, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 30, 2020 | May 11, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 27, 2019 | May 10, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.